Dr.Reddy's Laboratories Ltd Q4 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst : My first question, just a continuation of the operating costs. If I look at your SG&A spend, it was up in the last 2 quarters and had been inching up about INR 1,540 crores. How should I look at this going forward? Do you think the pace of the increase will be higher as we invest in digital, try to launch more products? Or do you think this is the level which is enough to sustain the growth that we have planned for the next 2 years?

Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst : Okay. Understood. And Erez, in your opening comment, you mentioned about the Russia market seeing some disruption in the quarter, which led to the quarter-on-quarter growth. If you could give just some color on that. And was this something one-off like some destocking? What led to this disruption? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 14, 2021 / 12:00PM, REDY.NS - Q4 2021 Dr.Reddy's Laboratories Ltd Earnings Call

Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst : For Russia. Yes, so Russia -- I think in your opening comments, you had mentioned some impact in the fourth quarter because of slowdown or disruption in the market. So if you could give some color on that.